Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Veteran Drops To The Ground When He Hears How Much His... January 31, 2020 New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage... October 18, 2025 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Load more HOT NEWS Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban Daughter Donates Hair to Mother After She Was Diagnosed with Stage... GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Resource Round-Up: Let’s Win Pancreatic Cancer
